Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Posted by Defense World Staff on May 6th, 2023

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $68.60.

A number of research analysts have recently issued reports on ENTA shares. Piper Sandler reaffirmed an “overweight” rating and set a $87.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, February 8th. JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $74.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 8th. Royal Bank of Canada reissued a “sector perform” rating and issued a $54.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday, March 22nd. HC Wainwright increased their target price on Enanta Pharmaceuticals from $56.00 to $68.00 in a report on Wednesday, February 8th. Finally, StockNews.com started coverage on Enanta Pharmaceuticals in a report on Thursday, March 16th. They issued a “hold” rating on the stock.

Insiders Place Their Bets

In other news, CFO Paul J. Mellett sold 5,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of $53.76, for a total transaction of $268,800.00. Following the sale, the chief financial officer now owns 83,463 shares of the company’s stock, valued at approximately $4,486,970.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Enanta Pharmaceuticals news, VP Yat Sun Or sold 13,925 shares of the business’s stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $44.45, for a total value of $618,966.25. Following the completion of the transaction, the vice president now owns 374,702 shares in the company, valued at $16,655,503.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Paul J. Mellett sold 5,000 shares of the business’s stock in a transaction on Thursday, February 9th. The stock was sold at an average price of $53.76, for a total transaction of $268,800.00. Following the transaction, the chief financial officer now owns 83,463 shares of the company’s stock, valued at approximately $4,486,970.88. The disclosure for this sale can be found here. Insiders have sold 57,277 shares of company stock valued at $2,612,121 in the last ninety days. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ENTA. Russell Investments Group Ltd. lifted its position in Enanta Pharmaceuticals by 2.9% in the third quarter. Russell Investments Group Ltd. now owns 21,324 shares of the biotechnology company’s stock valued at $1,105,000 after acquiring an additional 603 shares during the last quarter. Texas Permanent School Fund lifted its position in Enanta Pharmaceuticals by 5.2% in the third quarter. Texas Permanent School Fund now owns 14,016 shares of the biotechnology company’s stock valued at $727,000 after acquiring an additional 692 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in Enanta Pharmaceuticals by 7.7% in the third quarter. Cubist Systematic Strategies LLC now owns 40,323 shares of the biotechnology company’s stock valued at $2,092,000 after acquiring an additional 2,900 shares during the last quarter. Prudential Financial Inc. lifted its position in Enanta Pharmaceuticals by 4.6% in the third quarter. Prudential Financial Inc. now owns 19,749 shares of the biotechnology company’s stock valued at $1,024,000 after acquiring an additional 860 shares during the last quarter. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at about $482,000. Institutional investors and hedge funds own 93.68% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA stock opened at $36.02 on Friday. Enanta Pharmaceuticals has a fifty-two week low of $33.18 and a fifty-two week high of $76.36. The stock has a 50 day moving average price of $40.42 and a two-hundred day moving average price of $44.83. The company has a market capitalization of $752.46 million, a P/E ratio of -6.19 and a beta of 0.38.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last posted its earnings results on Tuesday, February 7th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.52) by $0.13. Enanta Pharmaceuticals had a negative return on equity of 36.59% and a negative net margin of 146.93%. The firm had revenue of $23.60 million for the quarter, compared to analysts’ expectations of $22.48 million. During the same period in the previous year, the firm earned ($1.48) earnings per share. The business’s revenue was down 14.5% compared to the same quarter last year. As a group, equities analysts predict that Enanta Pharmaceuticals will post -7.36 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

(Get Rating)

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.